Connect with us
JPMorgan Chase reduced its stake in Grifols from 3.09% to 2.99% as Brookfield seeks sovereign fund partners for a potential takeover bid. JPMorgan's 12.7 million shares...
Grifols shares rose 2.6% following reports that Canadian firm Brookfield is in informal talks with sovereign funds for a takeover bid. Brookfield is seeking €9.5 billion...
JPMorgan Chase reduced its stake in Grifols to 3.111%, down from a previous 3.458%, with 0.256% in voting rights and 2.855% through financial instruments. This follows...
Moody's withdrew Grifols' ratings, citing "insufficient or inadequate" information amid a potential takeover by family shareholders and Brookfield fund. Grifols' shares dropped, with Class A down...
Grifols can modify its complaint until September 9 or notify by August 13 if it will maintain it. Gotham has until September 12 to respond, Grifols...
Biotest, a Grifols group company, expects $1 billion in US sales of its immunoglobulin drug Yimmugo over the next seven years, following FDA approval. Grifols shares...
Grifols and PharmaMar significantly dropped Spanish pharmaceutical stocks, with declines of 49.1% and 22.5% respectively in the first half of 2024. Although other companies like Rovi...
Grifols rose almost 3% on the stock market at the start of the trading day this Friday, after the Catalan firm assured that it will be...
Grifols increased its private bond issue by €300 million, totaling €1.3 billion. The bonds, maturing in May 2030 with a 7.5% annual coupon, will repay part...
Goldman Sachs increased its stake in Grifols from 5.8% to 6.4%, amid a bearish attack by Gotham City Research, coinciding with Grifols' Q1 results. Melqart reduced...